Altimmune, Inc. (ALT)
After hours:
| Previous Close | 7.02 |
| Open | 7.06 |
| Bid | 7.50 x 1000 |
| Ask | 7.53 x 300 |
| Day's Range | 7.01 - 7.53 |
| 52 Week Range | 2.09 - 14.84 |
| Volume | |
| Avg. Volume | 3,502,798 |
| Market Cap | 532.476M |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.60 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 20, 2017 |
| 1y Target Est | 20.57 |
GlobeNewswireAltimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20
- GlobeNewswire
Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) will be presented at the EASL International Liver Congress™ 2024 in Milan, Italy. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for
PR NewswireRoundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)
Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs.
